发明名称 |
Pharmaceutical Combinations |
摘要 |
A pharmaceutical combination comprising (a) a protein kinase C (PKC) inhibitor compound, or a pharmaceutically acceptable salt thereof, and (b) at least one mitogen activated protein kinase (MEK) inhibitor or a pharmaceutically acceptable salt, and optionally a pharmaceutically acceptable carrier, for simultaneous, separate or sequential administration; the uses of such combination in the treatment of proliferative diseases; and methods of treating a subject suffering from a proliferative disease comprising administering a therapeutically effective amount of such combination. |
申请公布号 |
US2015306101(A1) |
申请公布日期 |
2015.10.29 |
申请号 |
US201314647939 |
申请日期 |
2013.11.26 |
申请人 |
PORTER Dale;EMERY Caroline;TAN Lujian;YERRAMILLI-RAO Padmaja |
发明人 |
Porter Dale;Emery Caroline;Tan Lujian;Yerramilli-Rao Padmaja |
分类号 |
A61K31/517;A61K31/4184 |
主分类号 |
A61K31/517 |
代理机构 |
|
代理人 |
|
主权项 |
1. A pharmaceutical combination comprising or consisting of:
(a) a protein kinase C (PKC) inhibitor compound, or a pharmaceutically acceptable salt thereof, and (b) a mitogen activated protein kinase (MEK) inhibitor compound, or a pharmaceutically acceptable salt thereof. |
地址 |
US |